If blood tests and physical examination reveal no other good explanation for the patient’s classic signs and symptoms of DTSF, then one may suspect an impairment in the conversion of T4 to T3 thyroid hormones and one may consider a therapeutic trial with the WT3 protocol. The goal of the WT3 protocol is really made up of two subgoals.
1. Feel well while on the WT3 protocol.
2. Remain well after the WT3 protocol has been discontinued.
These subgoals can be achieved separately or concurrently. During the course of treatment, the symptoms may resolve, but that doesn’t necessarily mean that they will stay resolved after therapy is weaned. Sometimes several cycles of treatment are necessary in order to have the symptoms resolve and remain resolved even after the WT3 protocol has been discontinued. Sometimes the symptoms resolve only after the WT3 protocol is discontinued. This is because the accomplishing of each subgoal is predicated upon a different factor. The first subgoal is predicated upon providing sufficiently normal and steady T3 levels to provide sufficiently normal and steady body temperature patterns to maintain normal enzyme activity, to eliminate and prevent the symptoms of MED characteristic of DTSF due to Wilson’s Temperature Syndrome. The second subgoal is predicated upon reversing the imbalance leading to impaired T4 to T3 conversion well enough that the body can maintain, on its own, proper thyroid system function once the WT3 protocol has been discontinued. The WT3 protocol accomplishes this goal by reducing competitive inhibition at the level of 5′-deiodinase by systematically reducing RT3 levels, and possibly by establishing a new pattern or new balance in the body’s overall system by indirectly effecting changes in other systems such as the female hormone system, adrenal hormone system, glucose metabolism system, and others (rope and ring analogy, see chapter 2).
Sometimes RT3 levels can be lowered to reduce their inhibition of T4 to T3 conversion, even though the artificial levels of T3 have not been stabilized sufficiently to completely eliminate the symptoms of MED. Yet, in such cases, with the underlying impairment corrected and the body’s own thyroid system function being restored as the WT3 protocol is gradually discontinued, the symptoms of MED may resolve more going off the WT3 protocol than they ever did while on the WT3 protocol. This demonstrates that the body’s own system can be “reset” to function properly on its own, even if the artificial T3 therapy could not be stabilized well enough (during a treatment cycle) to eliminate or prevent the symptoms of MED in the meantime. Usually both subgoals can be accomplished concurrently, but it should be remembered that they are not inseparable. It is fortunate that, in almost all cases, the two subgoals can be accomplished at the same time.